RDHL - RedHill Biopharma Ltd.
RedHill Biopharma Ltd.
21 Ha’arba’a Street
Tel Aviv 6473921
Israel
972 3 541 3131
https://www.redhillbio.com
Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full-time employees: 113
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Mr. Dror Ben-Asher | Co-Founder, CEO & Director | 734.59k | N/A | 1966 |
| Mr. Gilead Raday MPhil, MSc | Chief Operating Officer | 445.38k | N/A | 1975 |
| Mr. Adi Frish | Chief Corp. & Bus. Devel. Officer | 419.5k | N/A | 1970 |
| Mr. Rick D. Scruggs | Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director | 607.05k | N/A | 1960 |
| Mr. Micha Ben-Chorin | Advisor | 454.2k | N/A | 1969 |
| Mr. Razi Ingber | Chief Financial Officer | N/A | N/A | 1984 |
| Dr. Mark L. Levitt M.D., Ph.D. | Chief Scientific Officer | N/A | N/A | N/A |
| Ms. Alexandra Okmian | Sr. Bus. Devel. & Investor Relations Mang. | N/A | N/A | N/A |
| Kristin Comer | VP, Gen. Counsel & Chief Compliance Officer | N/A | N/A | N/A |
| Mr. Rob Jackson | Sr. VP of Sales & Marketing | N/A | N/A | N/A |
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Corporate governance
RedHill Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
